Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 13, 2020

SELL
$13.0 - $31.0 $712,400 - $1.7 Million
-54,800 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$10.63 - $15.37 $582,524 - $842,276
54,800 New
54,800 $712,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $90.6M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Ns Partners LTD Portfolio

Follow Ns Partners LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ns Partners LTD, based on Form 13F filings with the SEC.

News

Stay updated on Ns Partners LTD with notifications on news.